A groundbreaking collaborative study led by scientists based in Shanghai has identified a key gene that acts as a natural brake on Alzheimer’s disease progression, a discovery made possible by the creation of the world’s first in vivo functional map of regulatory molecular switches in brain astrocytes. The findings, published April 25, 2026 on the official website of the top peer-reviewed journal *Science*, mark a major new direction for Alzheimer’s treatment and open new doors for research into a wide range of other devastating neurological conditions.
The research brought together experts from three institutions: the Center for Excellence in Brain Science and Intelligence Technology under the Chinese Academy of Sciences, Shanghai Sixth People’s Hospital, and the Shanghai-based biotechnology firm Genemagic. Astrocytes, the most abundant non-neuronal cells in the human brain, play a critical role in supporting and protecting healthy neurons. When Alzheimer’s develops, however, these supportive cells undergo harmful dysfunction that speeds up neuronal death, a process that has been poorly understood by the scientific community until now.
To unpack how astrocyte function is regulated, the research team developed an innovative in vivo high-throughput sequencing platform called iGOFPerturb-seq, which enables large-scale, simultaneous analysis of transcription factor function — the molecular ‘switches’ that control how cells behave. The team used engineered adeno-associated viruses targeted specifically to astrocytes to deliver nearly 1,000 different transcription factors into the brains of laboratory mice, with each transcription factor tagged with a unique genetic barcode to track its effect. Using single-cell sequencing technology, the researchers analyzed nearly 400,000 individual astrocytes in parallel, linking each cell’s functional state to the specific transcription factor it had received. This method allowed them to assemble the first ever complete functional map of astrocyte regulatory switches in a living organism.
“This map is like a treasure map, helping scientists quickly identify candidate master regulators that can prevent astrocytes from becoming dysfunctional,” explained Zhou Haibo, the lead scientist of the study. From an initial pool of 39 promising regulatory molecules, the team identified Ferd3l, a transcription factor, as the most potent modifier capable of reversing astrocyte dysfunction in Alzheimer’s. To test the gene’s effectiveness, researchers activated Ferd3l in astrocytes of mouse models genetically engineered to develop human-like Alzheimer’s disease via intravenous injection. The treated mice saw dramatic improvements to their cognitive function, with performance on object recognition and maze tests nearly matching that of healthy control mice.
Zhang Liansheng, the first author of the published study, noted that further analysis revealed how Ferd3l works: it helps dysfunctional astrocytes re-establish healthy, cooperative interactions with both neurons and microglia — the brain’s primary resident immune cells — restoring functional order to the inflamed, disrupted brain environment characteristic of Alzheimer’s.
Unlike the majority of existing Alzheimer’s therapies, which focus exclusively on clearing beta-amyloid plaques from the brain, this new research targets astrocyte function, offering a complementary treatment strategy that could significantly improve long-term patient outcomes. In 2025, China launched an innovative beta-amyloid targeting therapy that has since been added to supplemental public health insurance coverage in major Chinese cities including Beijing, with clinical data showing sustained patient benefits even after treatment is stopped following successful plaque clearance.
Beyond Alzheimer’s, the study’s biggest impact may lie in its open-access resource: the full functional map of astrocyte regulators will be made available to research institutions and pharmaceutical companies across the globe, enabling scientists to search for similar ‘brake’ genes for other incurable neurological disorders including Parkinson’s disease and amyotrophic lateral sclerosis (ALS). The research also establishes a large library of potential new drug targets for a wide range of neurological conditions, accelerating the development of next-generation therapies for currently untreatable brain diseases.